GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EZZ Life Science Holdings Ltd (ASX:EZZ) » Definitions » ROE %

EZZ Life Science Holdings (ASX:EZZ) ROE % : 63.59% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is EZZ Life Science Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. EZZ Life Science Holdings's annualized net income for the quarter that ended in Jun. 2024 was A$11.64 Mil. EZZ Life Science Holdings's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was A$18.31 Mil. Therefore, EZZ Life Science Holdings's annualized ROE % for the quarter that ended in Jun. 2024 was 63.59%.

The historical rank and industry rank for EZZ Life Science Holdings's ROE % or its related term are showing as below:

ASX:EZZ' s ROE % Range Over the Past 10 Years
Min: 12.21   Med: 25.29   Max: 40.8
Current: 40.8

During the past 5 years, EZZ Life Science Holdings's highest ROE % was 40.80%. The lowest was 12.21%. And the median was 25.29%.

ASX:EZZ's ROE % is ranked better than
97.29% of 1328 companies
in the Biotechnology industry
Industry Median: -42.745 vs ASX:EZZ: 40.80

EZZ Life Science Holdings ROE % Historical Data

The historical data trend for EZZ Life Science Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EZZ Life Science Holdings ROE % Chart

EZZ Life Science Holdings Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24
ROE %
- 22.62 12.21 27.96 38.79

EZZ Life Science Holdings Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Get a 7-Day Free Trial 22.64 21.64 34.27 15.29 63.59

Competitive Comparison of EZZ Life Science Holdings's ROE %

For the Biotechnology subindustry, EZZ Life Science Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EZZ Life Science Holdings's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EZZ Life Science Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where EZZ Life Science Holdings's ROE % falls into.



EZZ Life Science Holdings ROE % Calculation

EZZ Life Science Holdings's annualized ROE % for the fiscal year that ended in Jun. 2024 is calculated as

ROE %=Net Income (A: Jun. 2024 )/( (Total Stockholders Equity (A: Jun. 2023 )+Total Stockholders Equity (A: Jun. 2024 ))/ count )
=6.964/( (14.582+21.323)/ 2 )
=6.964/17.9525
=38.79 %

EZZ Life Science Holdings's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=11.644/( (15.298+21.323)/ 2 )
=11.644/18.3105
=63.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


EZZ Life Science Holdings  (ASX:EZZ) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=11.644/18.3105
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(11.644 / 89.494)*(89.494 / 22.9245)*(22.9245 / 18.3105)
=Net Margin %*Asset Turnover*Equity Multiplier
=13.01 %*3.9039*1.252
=ROA %*Equity Multiplier
=50.79 %*1.252
=63.59 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=11.644/18.3105
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (11.644 / 16.866) * (16.866 / 16.446) * (16.446 / 89.494) * (89.494 / 22.9245) * (22.9245 / 18.3105)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.6904 * 1.0255 * 18.38 % * 3.9039 * 1.252
=63.59 %

Note: The net income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


EZZ Life Science Holdings ROE % Related Terms

Thank you for viewing the detailed overview of EZZ Life Science Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


EZZ Life Science Holdings Business Description

Traded in Other Exchanges
N/A
Address
104 Derby Street, Silverwater, NSW, AUS, 2128
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.

EZZ Life Science Holdings Headlines

No Headlines